BPC-157 + TB-500 Blend 15mg / 15mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of BPC-157 / TB-500 Blend supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF112025092

Key analytical results include:

• BPC-157 Assay Content: 15.51 mg
• BPC-157 Identification – Retention Time: 0.997
• TB-500 (Thymosin Beta-4) Assay Content: 15.41 mg
• TB-500 Identification – Retention Time: 0.989
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

The BPC-157 / TB-500 blend is a dual-peptide research preparation combining two synthetic peptides commonly investigated in experimental laboratory environments studying cellular signalling and peptide-mediated regulatory pathways.

The formulation combines BPC-157 and TB-500 within a single lyophilized preparation designed for controlled laboratory experimentation and comparative peptide interaction research.

This preparation contains a combined 30 mg of high purity lyophilized peptide material supplied in a sealed research vial. The lyophilization process preserves molecular stability and allows researchers to reconstitute the peptides for controlled in vitro experimentation.

Because of the defined peptide sequences and verified analytical profile, peptide combinations such as BPC-157 and TB-500 are frequently referenced in experimental research models exploring peptide signalling networks.

Compound Overview

BPC-157 is a synthetic peptide derived from a biologically active protein fragment identified during gastric peptide research.

TB-500 represents a synthetic form of the active region of thymosin beta-4, a protein involved in cellular structural dynamics and regulatory signalling systems.

Within biochemical research environments, both peptides are frequently investigated for their interactions with intracellular signalling pathways and cytoskeletal regulatory systems.

The combination of these peptides within a single preparation allows researchers to explore comparative peptide behaviour and interaction dynamics in controlled experimental models.

Historical Background and Scientific Context

Advances in peptide synthesis during the late twentieth century enabled researchers to isolate and replicate biologically active peptide fragments from larger proteins.

During the 1990s and early 2000s, research expanded into synthetic peptides capable of interacting with cellular signalling systems.

BPC-157 and thymosin-derived peptides subsequently became subjects of experimental research exploring peptide-mediated regulatory mechanisms and cellular signalling networks.

Modern laboratory investigations often analyse combinations of peptides to study signalling pathway interactions and comparative biochemical behaviour.

Mechanistic Focus in Research

Within experimental laboratory environments, the BPC-157 / TB-500 blend is studied in relation to peptide-mediated signalling pathways and molecular regulatory systems.

Research investigations commonly explore the peptides in experimental models examining:

• Peptide-receptor interaction mechanisms
• Cellular signalling pathway dynamics
• Cytoskeletal regulation systems
• Intracellular regulatory network modelling
• Comparative peptide interaction studies
• Molecular signalling cascade analysis
• Peptide-mediated biochemical processes

These experimental models allow scientists to investigate molecular regulatory mechanisms influencing cellular signalling behaviour and biochemical pathway interactions.

Research Applications

In controlled research environments, the BPC-157 / TB-500 blend may be utilised in experimental models designed to explore peptide signalling systems and intracellular regulatory pathways.

Examples of research applications include:

• Peptide signalling pathway investigation
• Comparative peptide interaction research
• Cell signalling analysis
• Molecular regulatory pathway studies
• Intracellular signalling network modelling
• Experimental biochemical peptide research
• Controlled in vitro peptide interaction studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

Verified and analysed with Liquilabs s.r.o. (Czechia)
High-purity dual research peptide blend
Validated assay content 15.51 mg BPC-157 and 15.41 mg TB-500
Retention time identification and full COA traceability
Endotoxin levels below 0.001 EU per mg
No detectable heavy metals or microbial growth
For research use only — not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.